





Aim To elucidate the involvement of noradrenergic system 
in the mechanism by which diazepam suppresses basal 
hypothalamic-pituitary-adrenal (HPA) axis activity.
Methods Plasma corticosterone and adrenocorticotropic 
hormone (ACTH) levels were determined in female rats 
treated with diazepam alone, as well as with diazepam in 
combination with clonidine (α2-adrenoreceptor agonist), 
yohimbine (α2-adrenoreceptor antagonist), alpha-methyl-
p-tyrosine (α-MPT, an inhibitor of catecholamine synthe-
sis), or reserpine (a catecholamine depleting drug) and yo-
himbine.
Results Diazepam administered in a dose of 2.0 mg/kg 
suppressed basal HPA axis activity, ie, decreased plasma 
corticosterone and ACTH levels. Pretreatment with cloni-
dine or yohimbine failed to affect basal plasma corticoster-
one and ACTH concentrations, but abolished diazepam-
induced inhibition of the HPA axis activity. Pretreatment 
with α-MPT, or with a combination of reserpine and yo-
himbine, increased plasma corticosterone and ACTH lev-
els  and  prevented  diazepam-induced  inhibition  of  the 
HPA axis activity.
Conclusion The results suggest that α2-adrenoreceptors 
activity, as well as intact presynaptic noradrenergic func-
tion, are required for the suppressive effect of diazepam on 
the HPA axis activity. Received: November 18, 2011
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Benzodiazepines  are  used  for  their  anxiolytic,  sedative-
hypnotic, muscle relaxant, and anticonvulsant properties 
in the treatment of a variety of neuropsychiatric disorders 
(1,2), including anxiety and depression, which are often re-
lated to disturbances in the activity of hypothalamic-pitu-
itary-adrenal (HPA) axis (3,4). Although these drugs exert 
most of their pharmacological effects via γ-aminobutyric 
acidA (GABAA) receptors (5,6), benzodiazepine administra-
tion has been associated with alterations in neuroendo-
crine function both in experimental animals and humans 
(7-9). However, even after years of extensive studies, the 
complex mechanisms by which these widely used drugs 
produce their effects on the HPA axis are still not known.
Although most of the previous studies have demonstrated 
that classical benzodiazepines such as diazepam decrease 
the HPA axis activity in stressful contexts (10-14), under basal 
conditions they have been shown to stimulate (9,11,15-18), 
inhibit (15,19-22), and not affect (17,23-25) the HPA axis ac-
tivity. Such diverse results might be related to several factors 
such as the dose and gender (15,16,20,21,26-28), or may also 
be a consequence of the net effect of non-selective benzo-
diazepines on the various GABAA receptor isoforms (9).
Our previous studies demonstrated that while diazepam 
(1 mg/kg) produced no change in plasma corticosterone 
levels in male rats (15,20), it decreased basal levels of corti-
costerone in female rats (15,26). However, although diaze-
pam inhibited the HPA axis activity of female rats following 
administration of lower doses (1 or 2 mg/kg) (15,20,21,26), 
it stimulated the HPA axis activity following administration 
of high doses (10 mg/kg) (15,16,26). Moreover, whereas 
the suppressive effect of the lower doses of diazepam (2.0 
mg/kg) on the HPA axis activity in female rats involves the 
GABAA receptor complex (21), increases in corticosterone 
levels by a higher dose of diazepam (10 mg/kg) do not in-
volve the stimulation of GABAA receptors (16). In addition, 
stimulatory effect of 10 mg/kg diazepam on the HPA axis 
activity in rats seems not to be mediated by the benzodi-
azepine/GABA/channel chloride complex or by peripheral 
benzodiazepine receptors, but rather by a cyclic adenosine 
monophosphate (AMP)-dependent mechanism (18).
Since our previous results suggested that the effect of a high 
dose of diazepam on the activity of the HPA axis in female rats 
might be due to a blockade of α2-adrenergic receptors (16), 
the aim of this study was to elucidate whether noradrener-
gic system also has a modulatory role in the inhibitory effect 
of 2.0 mg/kg diazepam on basal plasma adrenocorticotropic 
hormone (ACTH) and corticosterone levels in female rats.
MethoDs
Animals
Female adult Wistar rats (180-200 g), bred in our Institute, 
were housed under controlled conditions, with standard 
light-dark cycle and food and water freely available. The 
rats were caged in groups of five. Each experiment includ-
ed approximately 30-35 rats and was performed twice. The 
total number of animals used in the study was 260. To min-
imize circadian variability of plasma ACTH and corticoster-
one levels, all experiments were performed between 8.00 
and 12.00 a m The only exception was the experiment with 
reserpine in which reserpine was administered during the 
working and day-light time on the day prior to the experi-
ment, so that the administration of yohimbine and diaze-
pam, as well as sacrifice could be preformed until 12.00 a m 
of the next day. The phases of the estrous cycle of female 
rats were not monitored or synchronized prior to experi-
ments, since we presumed on the basis of previous stud-
ies (29-31) that the sexual cycle of female rats used in our 
study would not significantly affect diazepam-induced re-
ductions of basal plasma corticosterone or ACTH levels. Be-
fore the experiments, all animals were adapted to handling 
and intraperitoneal (ip) injecting for 7 days. All animal care 
and experimental procedures were carried out in accor-
dance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals (NIH publication No. 
86-23, revised 1996), and with the Croatian law on animal 
welfare. Ethical approval was received from the Ministry of 
Agriculture – Veterinary Directorate and Ruđer Bošković In-
stitute Ethics Review Board.
Drugs
Diazepam  (Krka,  Novo  Mesto,  Slovenia)  and  clonidine 
(Boehringer Ingelheim on Rhein, Germany) were dissolved 
in 0.1 N HCl, followed by saline. Yohimbine (Sigma Chemi-
cal Co, St. Luis, MO, USA) and α-methyl-p-tyrosine (α-MPT, 
Sigma) were dissolved in distilled water. Reserpine (Sigma) 
was suspended in glacial acetic acid and 5.5% glucose was 
added to the final volume. All drugs and corresponding ve-
hicles were prepared fresh, and after pH adjustment inject-
ed ip in a volume of 1 mL/100 g bw.
experimental procedure
Reserpine (10.0 mg/kg), alpha-methyl-p-tyrosine (400.0 
mg/kg),  yohimbine  (0.5  and  3.0  mg/kg),  clonidine 
(0.01 and 0.5 mg/kg), diazepam (2.0 mg/kg), or cor-BASIC SCIENCE  216 Croat Med J. 2012;53:214-23
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responding vehicles were injected ip 15h, 4h, 90-minute, 
35-minute, and 30-minute prior to sacrifice, respectively. 
The doses and time points of the drugs used in the study 
were selected based on the previous studies conducted 
in our laboratory and those reported in literature. Namely, 
since the results of our dose-response study (data available 
on request) revealed that the most significant decrease in 
plasma corticosterone levels was produced by the admin-
istration of 2.0 mg/kg diazepam, this dose was further used 
in our experiments. The two doses of clonidine (0.01 and 
0.5 mg/kg) were used with the aim to differentiate be-
tween presynaptic and postsynaptic effects of this drug 
(32,33). Yohimbine was administered in two doses (0.5 mg/
kg and 3 mg/kg), which have been already used in various 
studies (34,35). In order to ensure the complete inhibition 
of tyrosine hydroxylase, the enzyme responsible for cate-
cholamine synthesis, alpha-methyl-p-tyrosine (α-MPT) was 
administered in a high dose (400.0 mg/kg), previously re-
ported to inhibit catecholamine synthesis (36). To find out 
whether diazepam affects the HPA axis activity in condi-
tions which completely eliminate the noradrenergic trans-
mission, rats were pretreated with yohimbine (3.0 mg/kg) 
in a combination with reserpine administered in a high 
dose (10 mg/kg), already used for catecholamine deple-
tion by other authors (37). Animals were sacrificed by de-
capitation with a guillotine. Trunk blood was collected in 
prechilled tubes containing EDTA (1 mg/mL of blood), cen-
trifuged (4°C, 10-minute, 1250 g) and plasma was stored 
at -20°C. Corticosterone levels were determined in plasma 
samples of 500 μL by a slight modification of the fluoro-
metric method (21). ACTH levels were measured directly, 
without prior extraction, in a 200 µL of plasma, by a radio-
immunoassay using commercially available ACTHK-PR kit 
(CIS bioindustries, Gif sur Yvette, France).
Data analysis
Results were expressed as percents ± standard error of the 
mean of the values in control animals. Statistical evaluation 
of the results was done with GraphPad Prism version 4.00 
(GraphPad Software, San Diego, CA, USA) by using one-
way analysis of variance (ANOVA) followed by Tukey test. 
P-values of <0.05 were considered significant.
Results
The  administration  of  2.0  mg/kg  of  diazepam  to  fe-
male rats significantly reduced plasma corticosterone 
(P < 0.001) and ACTH (P < 0.01) levels. Both doses of 
clonidine (0.01 and 0.5 mg/kg) failed to affect plas-
ma corticosterone and ACTH levels in control rats, but clo-
nidine administered in a dose of 0.5 mg/kg antagonized 
diazepam-induced decrease of both hormones (P < 0.05) 
(Figure 1A and 1B). The administration of yohimbine in 
two doses (0.5 mg/kg and 3 mg/kg) elicited no effect on 
basal plasma corticosterone and ACTH levels. Although 
diazepam-induced  reduction  of  plasma  corticosterone 
levels  (P < 0.001)  was  reversed  already  with  0.5  mg/kg 
yohimbine (P < 0.01) (Figure 2A), the higher (3.0 mg/kg) 
dose of yohimbine was required to counteract (P < 0.001) 
the effect of diazepam (P < 0.01) on plasma ACTH levels 
(Figure 2B). The administration of α-MPT significantly in-
creased (P < 0.001) plasma corticosterone and ACTH lev-
els (Figure 3A and 3B). Although diazepam significantly 
decreased (P < 0.001) plasma corticosterone and ACTH 
FiguRe 1. the effect of clonidine on diazepam-induced 
decrease of plasma corticosterone (A) and adrenocorticotropic 
hormone (ACth) (B) concentrations. Clonidine (0.01 and 0.5 
mg/kg) or its vehicle and diazepam (2.0 mg/kg) or its vehicle 
were injected ip 35 and 30 minutes, respectively, prior to 
sacrifice. the results are expressed as percents ± standard error 
of the mean of the values in control animals treated with the 
corresponding vehicles. the number of animals per group was 
12 for determination of corticosterone levels and 7 for deter-
mination of ACth levels. *P < 0.01; †P < 0.001 vs the control 
vehicles-treated group; ‡P < 0.05 vs diazepam-treated group 
(one-way ANoVA followed by tukey test).217 Švob Štrac et al: Diazepam, noradrenaline, and HPA axis
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levels in control rats, it was unable to diminish the in-
crease of corticosterone and ACTH in the rats pretreated 
with α-MPT (Figure 3A and 3B). Plasma corticosterone lev-
els were similar between rats treated with α-MPT alone or 
α-MPT in combination with diazepam, but the combina-
tion of α-MPT and diazepam had an additive effect on 
plasma ACTH levels (P < 0.01). The combined treatment 
with reserpine and yohimbine induced a significant in-
crease (P < 0.001) in plasma corticosterone and ACTH lev-
els (Figure 4A and 4B). Diazepam significantly decreased 
plasma corticosterone and ACTH levels in control rats 
(P < 0.01), but could not suppress the elevated concen-
trations of both hormones in the rats pretreated with re-
serpine and yohimbine (Figure 4A and 4B).
DisCussioN
The observed inhibitory effect of 2.0 mg/kg diazepam on 
the HPA axis activity agrees with our previous studies that 
used the same (21) or similar (20,26) doses and timing of 
diazepam administration, but disagrees with some results 
which demonstrated no changes in the levels of corti-
costerone induced by diazepam treatment (23). Some 
of the discrepancies considering the effects of diaze-
pam on the basal HPA activity (stimulation, inhibi-
FiguRe 2. the effect of yohimbine on diazepam-induced 
decrease of plasma corticosterone (A) and adrenocorticotropic 
hormone (ACth) (B) concentrations. Yohimbine (0.5 and 3.0 
mg/kg) or its vehicle and diazepam (2.0 mg/kg) or its vehicle 
were injected ip 90 and 30 minutes, respectively, prior to sac-
rifice. the results are expressed as percents ± standard error of 
the mean of the values in control animals treated with the cor-
responding vehicles. the number of animals per group was 12 
for determination of corticosterone levels and 7 for determina-
tion of ACth levels. *P < 0.01; †P < 0.001 vs the control vehicles-
treated group; ‡P < 0.01; §P < 0.001 vs diazepam-treated group 
(one-way ANoVA followed by tukey test).
FiguRe 3. the effect of alpha-methyl-p-tyrosine (α-MPt) on 
diazepam-induced decrease of plasma corticosterone (A) 
and adrenocorticotropic hormone (ACth) (B) concentrations. 
Alpha-methyl-p-tyrosine (400.0 mg/kg) or its vehicle and 
diazepam (2.0 mg/kg) or its vehicle were injected ip 240 and 
30 minutes, respectively, prior to sacrifice. the results are ex-
pressed as percents ± standard error of the mean of the values 
in control animals treated with the corresponding vehicles. 
the number of animals per group was 15 for determination of 
corticosterone levels and 9 for determination of ACth levels. 
*P < 0.01 or P < 0.05 vs the control vehicles-treated group; 
†P < 0.001 vs the control vehicles-treated and diazepam-treat-
ed group; ‡P < 0.01 vs alpha-methyl-p-tyrosine-treated group 
(one-way ANoVA followed by tukey test).BASIC SCIENCE  218 Croat Med J. 2012;53:214-23
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tion, or no effect) could be ascribed to the differences in 
sex (15,20,28,38), age (13,39), basal vs stressful conditions 
(10,13,38), or the strain of the animals used (40).
The lack of an effect of clonidine on plasma corticoster-
one and ACTH levels observed in our study agrees with 
other  data  (41,42).  The  finding  that  pretreatment  with 
clonidine  counteracted  the  diazepam-induced  suppres-
sion of corticosterone and ACTH levels suggested that α2-
adrenoreceptors are probably involved in the inhibition of 
the HPA axis produced by diazepam. However, yohimbine 
also reversed the inhibitory effect of diazepam on plasma 
corticosterone and ACTH levels, and these results are in 
line with a study showing that yohimbine prevented de-
creases in both of these hormones induced by the intra-
ventricular administration of GABA (43).
The  fact  that  treatments  with  α2-adrenoreceptor  ago-
nist clonidine and α2-adrenoreceptor antagonist yohim-
bine had the same effects, ie, that both abolished diaze-
pam-induced inhibition of the HPA axis activity, might be 
explained by the pre- vs post-synaptic activities of these 
drugs. Namely, while the effect of clonidine administered 
in a dose of 0.5 mg/kg is likely to be produced by activation 
of postsynaptic α2-adrenoceptors (32), the observed effect 
of yohimbine is probably due to the blockade of inhibitory 
presynaptic α2-adrenoceptors, resulting in increased nora-
drenaline release (44). However, as the action of clonidine 
and yohimbine could be mediated by the activation or by 
the blockade of α2-adrenoreceptors (32,41,45), and as the 
drugs used are not absolutely selective, other more recep-
tor-distinctive agonists and/or antagonists might be useful 
in revealing the potential involvement of these receptors 
in diazepam-induced suppression of the HPA axis.
The results showing that diazepam was unable to coun-
teract the enhancement of corticosterone and ACTH lev-
els elicited by α-MPT (an inhibitor of tyrosine hydroxylase, 
the enzyme responsible for catecholamine synthesis), sug-
gested that diazepam suppresses the HPA axis activity by 
an action that also requires the intact presynaptic nora-
drenergic  function.  Moreover,  treatment  with  combina-
tion of reserpine (a catecholamine depleting drug) and yo-
himbine (a α2-adrenoreceptor antagonist), which creates 
a  condition  that  diminishes  noradrenergic  transmission, 
completely abolished the inhibitory effect of diazepam on 
plasma concentrations of corticosterone and ACTH. These 
results indicate that diazepam cannot exert any inhibitory 
influence when HPA axis is stimulated by drugs affecting 
noradrenergic neurotransmission such as α-MPT and reser-
pine, already reported to enhance corticosterone and/or 
ACTH levels (41,46,47).
To our knowledge, the present study was the first to dem-
onstrate that besides central benzodiazepine receptors, the 
part of GABAA receptor complex (21), α2-adrenoreceptors 
activity,  and  intact  presynaptic  noradrenergic  function 
were required for the suppressive effect of 2.0 mg/kg di-
FiguRe 4. the effect of combined pretreatment with reserpine 
and yohimbine on diazepam-induced decrease of plasma 
corticosterone (A) and adrenocorticotropic hormone (ACth) 
(B) concentrations. Reserpine (10.0 mg/kg) or its vehicle, 
yohimbine (3.0 mg/kg) or its vehicle, and diazepam (2.0 mg/
kg) or its vehicle were injected ip 15 hours, 90 minutes, and 
30 minutes, respectively, prior to sacrifice. the results are ex-
pressed as percents ± standard error of the mean of the values 
in control animals treated with the corresponding vehicles. 
the number of animals per group was 14 for determination of 
corticosterone levels and 7 for determination of ACth levels. 
*P < 0.01 vs the control vehicles-treated group; †P < 0.001 vs the 
control vehicles-treated and diazepam-treated group (one-
way ANoVA followed by tukey test).219 Švob Štrac et al: Diazepam, noradrenaline, and HPA axis
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azepam on the activity of the HPA axis in female rats. The 
suggestion that diazepam affects the HPA axis via nora-
drenergic system (Figure 5) also agrees with the previously 
shown interactions between diazepam and noradrenergic 
function (48-50).
However, the fact that diazepam (1 mg/kg) produced no 
change in basal plasma corticosterone levels in male rats 
(15,20)  points  out  differences  in  the  regulatory  mecha-
nisms of the HPA axis activity between males and females 
(10,30,38,51,52). These findings are in line with the studies 
demonstrating that the effects of benzodiazepine expo-
sure on CRH system, including corticosterone and ACTH 
levels,  are  influenced  by  gender-related  factors  (27,30). 
Namely,  gonadal  steroid  hormones  including  estrogens 
and androgens have been shown to modulate the GABA/
BZ receptors or their responses, as well as the HPA axis ac-
tivity implicated in the different stress responses between 
genders  (27,30,53,54).  Moreover,  sexually  dimorphic  al-
ternations in CRH system and HPA responses to stress are 
suggested to play a role in the etiology of affective and 
anxiety-related disorders and may be affected by both es-
trogen and progesterone (27).
Such neuropsychiatric conditions have been also associ-
ated  with  perturbations  of  endogenous  neurosteroids 
within the CNS (55,56), Neurosteroid levels are dynami-
cally regulated in response to a number of physiological 
states, such as stress, development, puberty, pregnancy, 
menopause, and during the ovarian cycle (57,58). In addi-
tion, it has been demonstrated that treatment with certain 
psychoactive drugs can affect neurosteroid content in the 
brain (59,60). Namely, certain benzodiazepines including 
diazepam, besides enhancing the GABAA receptor func-
tion, have been shown to promote the synthesis of neuro-
steroids (61,62). Hence, in agreement with the known role 
of neurosteroids as potent positive allosteric modulators 
of GABA action at GABAA receptors (62), the effects of di-
azepam might be potentiated by endogenous neuroster-
oids (63). As neurosteroids participate in the homeostatic 
regulation of HPA axis under basal as well as stress condi-
tions (64), they could also contribute to diazepam-induced 
suppression of HPA axis activity, by additionally decreasing 
ACTH and corticosterone levels, especially during stress 
when rapid elevation of neurosteroid levels occurs (65,66).
In conclusion, our present and previous (16) data suggest-
ed that noradrenergic system might have an important 
modulatory role in the suppressive as well as in the stimu-
latory effects of diazepam on the HPA axis activity in female 
rats. As disturbances in the HPA axis activity are found in a 
variety of psychiatric disorders that are treated with ben-
FiguRe 5. hypothetical mechanisms involved in the inhibitory effect of diazepam on the hypothalamic-pituitary-adrenal (hPA) axis 
activity – modified from Carrasco et al (12). the γ-amino-butyric acid (gABA) system is involved in the regulation of the hPA activity 
via inhibition of corticotrophin-releasing hormone (CRh) and noradrenergic neurons (A). the diazepam-enhanced gABAergic neu-
rotransmission results in the increased inhibition of CRh neurons in the hypothalamic paraventricular nucleus (PVN) and conse-
quently in the decrease of plasma adrenocorticotropic hormone (ACth) and glucocorticoid levels (B). however, this inhibitory effect 
of diazepam could be achieved, besides direct gABAergic inputs to CRh neurons, also by the interaction of gABAergic neurons from 
the surrounding hypothalamic regions and noradrenergic neurons in the locus coeruleus (lC), which also exhibit reciprocal neural 
connections with CRh neurons in PVN (C). this hypothesis is supported by our results demonstrating that intact noradrenergic 
function is essential for the diazepam-induced suppression of the hPA axis activity, while activation of postsynaptic or blockade of 
presynaptic α2-noradrenergic receptors reduces inhibitory effect of diazepam.BASIC SCIENCE  220 Croat Med J. 2012;53:214-23
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zodiazepines,  including  depression,  insomnia,  and  anxi-
ety (3,4), we could speculate that the therapeutic effects 
of benzodiazepines might be achieved not only by their 
well-known mechanisms, but also through modulation of 
the HPA axis activity via noradrenergic system. Consider-
ing the fact that mood and anxiety disorders as well as use 
of benzodiazepines are highly prevalent among women 
(28,67,68), these findings might be relevant for the ther-
apeutic implications in female population. This might be 
particularly the case in the combined treatment of ben-
zodiazepines and antidepressants, such as tricyclic anti-
depressants,  noradrenaline  reuptake  inhibitors,  and  se-
rotonin-noradrenaline  reuptake  inhibitors  (69,70).  These 
combinations are especially common in the treatment of 
co-morbid depression and anxiety. Since some antidepres-
sant drugs might affect the noradrenergic neurotransmis-
sion, which seems to be involved in the opposite effects of 
different doses of diazepam on the HPA axis activity, a spe-
cial attention should be given to adjustment of particular 
doses of benzodiazepines and antidepressants, when used 
in combination.
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